PR: Metabrain Research and ImaBiotech initiate a strategic partnership to offer cutting-edge preclinical research services in metabolic disorders.

Lille, 17th January 2019

Metabrain Research and ImaBiotech have announced the launch of a new preclinical service for Biotech-Pharma-MedTech companies allowing the measurement of tissue distribution, pharmacokinetic and pharmacodynamic (PK/PD) drug effects in preclinical metabolic disorders models.
This innovative joint offer will combine ImaBiotech’s state of the art platforms in bioanalysis to measure and confirm the efficacy of a drug at the cellular level and Metabrain Research’s mastery to develop new molecules in metabolic age-related diseases such as NASH, diabetes, sarcopenia and related immuno-inflammatory disorders.

Dr. David Bonnel, Executive Director at ImaBiotech (France), commented, “ImaBiotech is proud to extend its preclinical research services with this new partnership dedicated to metabolic disorders. Metabrain Research has developed this past decade an impressive expertise in this therapeutic area based on specific diseases models. The combination of our platforms will reinforce our capabilities and the possibility for our sponsors to evaluate their drug mechanism of action and efficacy in this therapeutic field from early to late stages.”

Dr. Valérie Autier, CEO of Metabrain Research, added, “We act daily, to better characterize the mechanism and the site of action of drugs. We’ve been very impressed by the precision and the potency of Imabiotech’s technology. Through this new combination of expertise, our clients will gain access to the most powerful tool dedicated to the hit and lead selection and their optimization into preclinical candidates.

Download it

Search news